Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.
Bide Pharmatech Co. Ltd. A (688073) - Total Assets
Latest total assets as of June 2025: CN¥2.53 Billion CNY
Based on the latest financial reports, Bide Pharmatech Co. Ltd. A (688073) holds total assets worth CN¥2.53 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bide Pharmatech Co. Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how Bide Pharmatech Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bide Pharmatech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Bide Pharmatech Co. Ltd. A's total assets of CN¥2.53 Billion consist of 91.3% current assets and 8.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 45.7% |
| Accounts Receivable | CN¥222.95 Million | 9.2% |
| Inventory | CN¥760.22 Million | 31.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥3.95 Million | 0.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Bide Pharmatech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bide Pharmatech Co. Ltd. A's current assets represent 91.3% of total assets in 2024, an increase from 85.9% in 2020.
- Cash Position: Cash and equivalents constituted 45.7% of total assets in 2024, up from 17.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 31.4% of total assets.
Bide Pharmatech Co. Ltd. A Competitors by Total Assets
Key competitors of Bide Pharmatech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Bide Pharmatech Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bide Pharmatech Co. Ltd. A generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Bide Pharmatech Co. Ltd. A generates $ 4.86 in net profit.
Bide Pharmatech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.31 | 7.35 | 7.65 |
| Quick Ratio | 2.74 | 5.04 | 5.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.79 Billion | CN¥ 1.88 Billion | CN¥ 1.91 Billion |
Bide Pharmatech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Bide Pharmatech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.71 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | CN¥2.42 Billion |
| Market Capitalization | $208.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bide Pharmatech Co. Ltd. A's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bide Pharmatech Co. Ltd. A's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bide Pharmatech Co. Ltd. A (2020–2024)
The table below shows the annual total assets of Bide Pharmatech Co. Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.42 Billion | +0.12% |
| 2023-12-31 | CN¥2.42 Billion | +2.37% |
| 2022-12-31 | CN¥2.36 Billion | +160.36% |
| 2021-12-31 | CN¥906.13 Million | +70.36% |
| 2020-12-31 | CN¥531.90 Million | -- |